Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Compaq -- Ignore unavailable to you. Want to Upgrade?

To: Elwood P. Dowd who wrote (93135)	9/19/2001 11:58:52 PM
From: Jimbo Cobb	Respond to of 97611

The biggest losers so far have been Compaq shareholders, but that struggling company is in no shape to go it alone anyway, said Bear Stearns analyst Andrew Neff, who has long argued the industry faces consolidation. ``I still think Compaq needs this deal to happen,'' Neff said.

To: Elwood P. Dowd who wrote (93135)	9/20/2001 2:55:06 PM
From: Night Writer	Read Replies (3) \| Respond to of 97611

Structural GenomiX and Compaq to Build Multi-Million Dollar State-of-the-Art Data Center for Structural Informatics Compaq's High Performance Technical Computing Will Advance SGX's Drug Discovery Efforts SAN DIEGO, Sept. 20 /PRNewswire/ -- Structural GenomiX (SGX) today announced a multi-million dollar agreement with Compaq Computer Corporation (NYSE: CPQ) to develop SGX's high performance structural informatics systems. SGX will purchase a complete Compaq technology solution including Compaq AlphaServer(R) systems running Tru64(TM) UNIX(R), market-leading Compaq ProLiant(R) industry-standard servers running Linux, StorageWorks(R) and services. Compaq's Alpha chip technology and leadership in building high performance computing systems will advance SGX's drug discovery efforts by increasing SGX's ability to run its high-throughput protein modeling, molecular dynamics and chemical docking programs on a genomic scale. As the leader in high performance computing for genomics and proteomics, Compaq was selected based on its ability to expand SGX's drug discovery efforts through its industry leading technology and experience in life sciences computing. The technology and services provided by Compaq will assist SGX and its partners in target identification and validation, lead selection and screening, and optimization of compounds for binding and selectivity, with the goal of improving drug efficacy as well as predicting and avoiding toxicity and negative side effects. As part of the agreement, Compaq will build and install a high performance computing system consisting initially of 200 Tru64 UNIX-based AlphaServer DS10L systems, two AlphaServer GS80 systems in a TruCluster, one AlphaServer ES40 system, and a 140-processor Linux-based Compaq ProLiant server cluster. SGX will also receive system upgrades, support services, and early access to new technologies, including access to the Intel(R) Itanium(TM) microprocessor architecture. "Compaq's technology and support will enhance our structural informatics capabilities, allowing us to model and compare more target structures and computationally explore more lead compounds than competing systems," said Tim Harris, Ph.D., SGX's President and CEO. "In the search for an IT partner, SGX selected an organization that has dedicated its efforts and resources to the life sciences field. I believe our relationship with Compaq in structural genomics computing is the foundation for a comprehensive understanding of protein structures and small molecule interactions and will rapidly scale up SGX's drug discovery process." "Compaq is pleased to be selected as Structural GenomiX's information technology provider to power their leading-edge structure based drug discovery efforts," said Bill Blake, Vice President of Compaq's High Performance Technical Computing Group. "SGX is an emerging player in the genome technology arena, and Compaq's IT solutions will assist SGX in significantly expanding their research capabilities and achieving their long-term business goals." Structural GenomiX (SGX) is a leader in experimental and computational structural biology, transforming genomic information into structural templates for drug discovery. SGX technologies include advanced bioinformatics tools for target selection and structure annotation, automation of molecular biology and protein biochemistry, high-throughput crystallization, protein structure prediction by comparative modeling and ab initio methods, synthetic and computational chemistry, and rapid co-complex structure determination. SGX has a dedicated world-class facility for the collection of macromolecular X-ray diffraction data at the Advanced Photon Source (APS) at the U.S. Department of Energy's Argonne National Laboratory. SGX's programs include 3D-ID(TM), a program leveraging SGX technologies toward the discovery and design of novel anti-infectives, protein kinase and nuclear receptor structural genomics programs, and a five-year $13M strategic alliance with the Cystic Fibrosis Foundation focused on membrane protein structure prediction and crystallography. SGX is headquartered in San Diego with additional locations in San Francisco and Argonne, IL. For more information, please visit the Company website at stromix.com.

To: Elwood P. Dowd who wrote (93135)	9/21/2001 1:53:03 PM
From: John Koligman	Read Replies (1) \| Respond to of 97611

Elwood, since you are a regular at the corner bar.... Best regards, John To:pat mudge who started this subject From: Carl Shaw Friday, Sep 21, 2001 1:09 PM Respond to of 2575 OT:Found on another board..... Interesting stock news for you savvy investors!! Point of Interest If you bought $1000 worth of Nortel stock one year ago, it would now be worth $49. If you bought $1000 worth of Budweiser (the beer, not the stock one year ago, drank all the beer, and traded in the cans for the nickel deposit, you would have $79. My advice to you is to start drinking heavily.